<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096898</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0941</org_study_id>
    <nct_id>NCT04096898</nct_id>
  </id_info>
  <brief_title>Senofilcon A Lenses in Moderate to Severe Dry Eye Disease</brief_title>
  <official_title>Clinical Trial to Determine Whether Senofilcon A Lenses Provide Relief of Symptoms and Signs in Patients With Moderate to Severe Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial using Senofilcon A daily lenses in the treatment of moderate to severe dry
      eye. This a comparison between signs and symptoms prior to and during treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      32 patients with moderate to severe dry eye will be enrolled in this short-term proof of
      concept study to determine the efficacy in using soft lenses made of Senofilcon A in reducing
      signs and symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patient questionaire</description>
  </primary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Moderate to Severe Dry Eye Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Senofilcon A contact lens</intervention_name>
    <description>Senofilcon lenses will be tested in moderate to severe dry eye patients to determine their efficacy in reducing discomfort associated with dry eye.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of moderate to severe dry eye associated with either
             Graft-versus-host disease (GVHD), Sjogren syndrome, idiopathic dry eyes, or minimal
             limbal cell deficiency

          -  A baseline Schirmer tear test (1) of less than 5 mm at 5 minutes without anesthesia

          -  Have a visual analog score for comfort of 50 or less (scale of 1-100, with 100 meaning
             perfect ocular comfort and 1 meaning severe ocular pain)

          -  Ability or the resources to insert and remove the study lenses

          -  An OSDI score greater than 42

          -  A willingness to sign an informed consent

        Exclusion Criteria:

          -  No dry eyes or mild dry eyes

          -  A baseline Schirmer tear test (1) of greater than 5 mm of wetting at 5 minutes

          -  Dry eye comfort score of greater than 50 on a visual analog scale

          -  Unable to insert or remove the study lenses (or have a family member do so)

          -  Have an OSDI score less than 42

          -  Has been diagnosed with neurotrophic keratopathy in either eye

          -  Unwilling to enroll in the study, and unwilling to provide signed informed consent to
             participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy T McMahon, OD</last_name>
    <phone>312-996-5410</phone>
    <email>timomcma@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob Merriman</last_name>
    <phone>312-996-8041</phone>
    <email>jmerr@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Merriman</last_name>
      <phone>312-996-8041</phone>
      <email>jmerr@uic.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Timothy T. McMahon, OD</investigator_full_name>
    <investigator_title>Dr. Timothy T. McMahon</investigator_title>
  </responsible_party>
  <keyword>dry eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

